The main therapeutic areas and applicable groups of enzalutamide/enzalutamide

Enzalutamide/Enzalutamide is a prescription drug specially designed for male patients with prostate cancer. It has a wide range of therapeutic areas and covers a variety of prostate cancer scenarios. Specifically, it plays an important role in the treatment of the following types of prostate cancer:

1)Castration-resistant prostate cancer (CRPC): Enzalutamide has shown unique efficacy in prostate cancer that has become resistant to traditional testosterone-lowering hormone therapy or surgery.

2) Metastatic castration-sensitive prostate cancer (mCSPC): Enzalutamide is also an effective treatment option when prostate cancer has spread to other parts of the body but remains sensitive to testosterone-lowering treatments.

3) Biochemically recurrent non-metastatic castration-sensitive prostate cancer (nmCSPC) with high risk of metastasis (high-risk BCR): Enzalutamide also provides important therapeutic support for patients whose cancer has not metastasized but is at high risk of metastasis and who still respond to testosterone-lowering therapy.

There is currently insufficient research support on the safety and efficacy of enzalutamide in women and children. Therefore, in current clinical practice, this drug is still mainly used by male prostate cancer patients. The core mechanism of enzalutamide is to effectively inhibit the growth and spread of tumors by blocking the binding of testosterone to receptors on prostate cancer cells. It can be used as the first choice treatment for prostate cancer or as an adjunct after other treatments to help patients better control their disease and thereby improve their quality of life.

However, patients may experience side effects such as fatigue, insomnia, dizziness, high blood pressure, and nausea when treated with enzalutamide. Therefore, during the treatment process, doctors need to pay close attention to the patient's physical condition and drug response to ensure timely adjustment of the treatment plan to minimize the occurrence of adverse reactions.